Debt-to-equity of Spyre Therapeutics, Inc. from 30 Sep 2016 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Spyre Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 31 Dec 2025.
  • Spyre Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 13%, a 44% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 13% -11% -44% 31 Dec 2025
Q3 2025 16% -14% -46% 30 Sep 2025
Q2 2025 20% -41% -67% 30 Jun 2025
Q1 2025 20% +427% 31 Mar 2025
Q4 2024 24% +199% 31 Dec 2024
Q3 2024 30% +127% 30 Sep 2024
Q2 2024 61% +629% 30 Jun 2024
Q1 2024 -407% -444% -1213% 31 Mar 2024
Q4 2023 -175% -209% -619% 31 Dec 2023
Q3 2023 -97% -129% -407% 30 Sep 2023
Q2 2023 -568% -597% -2042% 30 Jun 2023
Q1 2023 37% +8.6% +31% 31 Mar 2023
Q4 2022 34% +5.6% +20% 31 Dec 2022
Q3 2022 32% +7.6% +32% 30 Sep 2022
Q2 2022 29% +8.2% +39% 30 Jun 2022
Q1 2022 28% +9.5% +52% 31 Mar 2022
Q4 2021 28% +10% +58% 31 Dec 2021
Q3 2021 24% +2.3% +11% 30 Sep 2021
Q2 2021 21% -4.7% -18% 30 Jun 2021
Q1 2021 18% -11% -38% 31 Mar 2021
Q4 2020 18% -2.9% -14% 31 Dec 2020
Q3 2020 22% +5% +30% 30 Sep 2020
Q2 2020 26% +12% +86% 30 Jun 2020
Q1 2020 29% +18% +160% 31 Mar 2020
Q4 2019 21% +8.6% +71% 31 Dec 2019
Q3 2019 17% +5.7% +52% 30 Sep 2019
Q2 2019 14% +3.6% +35% 30 Jun 2019
Q1 2019 11% +1.4% +14% 31 Mar 2019
Q4 2018 12% +3.5% +41% 31 Dec 2018
Q3 2018 11% +3.6% +48% 30 Sep 2018
Q2 2018 10% +3.6% +55% 30 Jun 2018
Q1 2018 10% +4.1% +69% 31 Mar 2018
Q4 2017 8.6% +0.07% +0.88% 31 Dec 2017
Q3 2017 7.4% -7.2% -49% 30 Sep 2017
Q2 2017 6.6% 30 Jun 2017
Q1 2017 5.9% 31 Mar 2017
Q4 2016 8.5% 31 Dec 2016
Q3 2016 15% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.